Violich Capital Management Inc. Trims Holdings in Johnson & Johnson (NYSE:JNJ)

Violich Capital Management Inc. decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.9% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 92,574 shares of the company’s stock after selling 1,760 shares during the quarter. Johnson & Johnson makes up about 2.4% of Violich Capital Management Inc.’s investment portfolio, making the stock its 13th largest position. Violich Capital Management Inc.’s holdings in Johnson & Johnson were worth $14,510,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Hibernia Wealth Partners LLC purchased a new stake in Johnson & Johnson in the third quarter valued at $27,000. FNY Investment Advisers LLC purchased a new stake in Johnson & Johnson in the third quarter valued at $37,000. Keener Financial Planning LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at $40,000. Tower View Wealth Management LLC grew its stake in shares of Johnson & Johnson by 183.3% in the third quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock valued at $40,000 after buying an additional 165 shares in the last quarter. Finally, Creative Capital Management Investments LLC grew its stake in shares of Johnson & Johnson by 43.0% in the third quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock valued at $45,000 after buying an additional 86 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, February 28th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research note on Monday. Morgan Stanley lowered their target price on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 24th. Finally, Raymond James upped their price target on Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. Seven investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $177.31.

Johnson & Johnson Trading Down 0.0 %

JNJ opened at $147.49 on Tuesday. Johnson & Johnson has a one year low of $144.95 and a one year high of $175.97. The company has a market cap of $355.42 billion, a P/E ratio of 10.68, a PEG ratio of 2.48 and a beta of 0.53. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.91 and a current ratio of 1.16. The business’s 50-day simple moving average is $157.07 and its 200-day simple moving average is $155.90.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, beating analysts’ consensus estimates of $2.28 by $0.01. Johnson & Johnson had a return on equity of 37.27% and a net margin of 37.79%. The business had revenue of $21.40 billion for the quarter, compared to the consensus estimate of $21.02 billion. During the same quarter in the prior year, the business posted $2.35 EPS. The business’s revenue for the quarter was down 9.7% on a year-over-year basis. As a group, equities research analysts expect that Johnson & Johnson will post 10.66 EPS for the current fiscal year.

Insider Activity

In related news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the sale, the insider now directly owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the sale, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the sale, the insider now directly owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.